We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
Read MoreHide Full Article
Exact Sciences Corporation (EXAS - Free Report) recently announced the selection of its testing laboratory in Phoenix, AZ, for ComboMATCH clinical trials. The company will use its new OncoExTra test to analyze tumor tissue and pair normal blood samples from patient participants to uncover specific abnormalities in a patient's tumor, which is most effective for treatment.
The recent development reinforces Exact Sciences’ commitment to providing comprehensive tumor information for patients and enabling the delivery of personalized cancer care.
About ComboMATCH Trial
ComboMATCH is a coordinated set of precision medicine cancer clinical trials led by the ECOG-ACRIN Cancer Research Group and National Cancer Institute (“NCI”) through its National Clinical Trials Network. The ComboMATCH registration trial is the gateway to a coordinated set of clinical trials to evaluate new anti-cancer treatment combinations directed by next-generation sequencing (NGS) testing. The trial will assign people in select groups of adults and children with locally advanced or advanced (metastatic) cancer.
Image Source: Zacks Investment Research
News in Detail
OncoExTra belongs to Exact Sciences’ growing portfolio of cancer solutions across the cancer-care continuum, which was introduced earlier in February 2023. The test provides a comprehensive molecular picture of the patient's cancer and actionable results, matching a patient's unique cancer to a targeted therapy or clinical trial.
The OncoExTra test works by profiling the entire exome (DNA) and the transcriptome (RNA) across approximately 20,000 genes, uncovering variants possibly missed by only evaluating DNA. It also uses matched tumor-normal sequencing to limit potentially false positive results and allows physicians to make clinical decisions based on variants related only to the tumor. OncoExTra also analyzes all National Comprehensive Cancer Network-recommended genes for patients with solid tumors and provides expertly curated, intuitive reports.
As part of ComboMATCH trials, the OncoExTra test will be used to provide the most informed picture of a patient's individual tumor biology.
Industry Prospects
Per a Research report, the global clinical oncology NGS market was valued at $370 million in 2022 and is expected to witness a CAGR of 15.7% by 2030.
Other Highlights in Precision Oncology
In the second quarter of 2023, the company secured reimbursements for the Oncotype DX Breast test in Japan. Outside the United States, Japan represents the biggest opportunity where 90,000 women are diagnosed with breast cancer every year.
Further, EXAS announced positive top-line results from the BLUE-C study, wherein the next-generation Cologuard test exceeded the company’s expectations for improved sensitivity and specificity. In June 2023, Exact Sciences initiated collaborations with the Broad Institute of MIT and Harvard to support its molecular residual disease test platform and Baylor Scott & White to support the multi-cancer early detection program.
Price Performance
In the past six months, Shares of EXAS have surged 133% against the industry’s decline of 7.1%.
Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Shares of HealthEquity have risen 3% in the past year. Earnings estimates for HQY have remained constant at $1.92 for 2023 and have moved up from $2.47 to $2.48 for 2024 in the past 30 days.
HealthEquity’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 9.10%. In the last reported quarter, it posted an earnings surprise of 21.95%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have increased 182.2% in the past year compared with the industry’s rise of 0.6%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 38% in the past year compared with the industry’s rise of 5.8%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
Exact Sciences Corporation (EXAS - Free Report) recently announced the selection of its testing laboratory in Phoenix, AZ, for ComboMATCH clinical trials. The company will use its new OncoExTra test to analyze tumor tissue and pair normal blood samples from patient participants to uncover specific abnormalities in a patient's tumor, which is most effective for treatment.
The recent development reinforces Exact Sciences’ commitment to providing comprehensive tumor information for patients and enabling the delivery of personalized cancer care.
About ComboMATCH Trial
ComboMATCH is a coordinated set of precision medicine cancer clinical trials led by the ECOG-ACRIN Cancer Research Group and National Cancer Institute (“NCI”) through its National Clinical Trials Network. The ComboMATCH registration trial is the gateway to a coordinated set of clinical trials to evaluate new anti-cancer treatment combinations directed by next-generation sequencing (NGS) testing. The trial will assign people in select groups of adults and children with locally advanced or advanced (metastatic) cancer.
Image Source: Zacks Investment Research
News in Detail
OncoExTra belongs to Exact Sciences’ growing portfolio of cancer solutions across the cancer-care continuum, which was introduced earlier in February 2023. The test provides a comprehensive molecular picture of the patient's cancer and actionable results, matching a patient's unique cancer to a targeted therapy or clinical trial.
The OncoExTra test works by profiling the entire exome (DNA) and the transcriptome (RNA) across approximately 20,000 genes, uncovering variants possibly missed by only evaluating DNA. It also uses matched tumor-normal sequencing to limit potentially false positive results and allows physicians to make clinical decisions based on variants related only to the tumor. OncoExTra also analyzes all National Comprehensive Cancer Network-recommended genes for patients with solid tumors and provides expertly curated, intuitive reports.
As part of ComboMATCH trials, the OncoExTra test will be used to provide the most informed picture of a patient's individual tumor biology.
Industry Prospects
Per a Research report, the global clinical oncology NGS market was valued at $370 million in 2022 and is expected to witness a CAGR of 15.7% by 2030.
Other Highlights in Precision Oncology
In the second quarter of 2023, the company secured reimbursements for the Oncotype DX Breast test in Japan. Outside the United States, Japan represents the biggest opportunity where 90,000 women are diagnosed with breast cancer every year.
Further, EXAS announced positive top-line results from the BLUE-C study, wherein the next-generation Cologuard test exceeded the company’s expectations for improved sensitivity and specificity. In June 2023, Exact Sciences initiated collaborations with the Broad Institute of MIT and Harvard to support its molecular residual disease test platform and Baylor Scott & White to support the multi-cancer early detection program.
Price Performance
In the past six months, Shares of EXAS have surged 133% against the industry’s decline of 7.1%.
Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are HealthEquity (HQY - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of HealthEquity have risen 3% in the past year. Earnings estimates for HQY have remained constant at $1.92 for 2023 and have moved up from $2.47 to $2.48 for 2024 in the past 30 days.
HealthEquity’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 9.10%. In the last reported quarter, it posted an earnings surprise of 21.95%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have increased 182.2% in the past year compared with the industry’s rise of 0.6%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 38% in the past year compared with the industry’s rise of 5.8%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.